GLENMARK PHARMACEUTICALS LTD. - Press Release

Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR With reference to the subject mentioned above, kindly find attached media release which is self-explanatory. Request you to kindly take the same on record.